Cancer Advance Package- Male

35 Tests | Rs 1499 | Blood Tests Only | Fasting Not Needed | Reports In 15 Hours
Powered By Redcliffelabs CBC, CEA, PSA Total, PSA Free, PSA Free/Total Ratio, CA 19.9
  1. CA 19.9 (Pancreatic Cancer Marker) (1)
    1. Ca 19.9
  2. Carcinoembryonic Antigen (CEA). (1)
    1. CEA
  3. Complete Blood Count (CBC) (26)
    1. Absolute Basophils Count, Blood
    2. Absolute Eosinophil Count, Blood
    3. Absolute Lymphocyte Count, Blood
    4. Absolute Monocyte Count, Blood
    5. Absolute Neutrophil Count, Blood
    6. Basophils
    7. Eosinophils
    8. Hemoglobin Hb
    9. Lymphocytes
    10. MCH
    11. MCHC
    12. MCV
    14. Monocytes
    15. MPV Mean Platelet Volume
    16. Neutrophils
    17. PCT
    18. PCV Haematocrit
    19. PDW Platelet Distribution Width
    20. Platelet Count Thrombocyte count
    21. P – LCC
    22. P – LCR
    23. RBC Count
    24. RDW-CV
    25. RDW (Red Cell Distribution Width)
    26. WBC-Total Counts Leucocytes
  4. Prostate Specific Antigen (PSA) Free (1)
    1. Prostate Specific Antigen (PSA) Free
  5. Prostate Specific Antigen (PSA) Profile (5)
    1. Free Beta HCG
    2. Free PSA Ratio
    3. Free PSA / Total PSA Ratio
    4. PSA- Free
    5. PSA- Total
  6. Prostate Specific Antigen (PSA) Total (1)
    1. PSA – Total (Prostate Specific Antigen)

The “Cancer Advance Package- Male” offered by Redcliffelabs is a diagnostic package specifically designed for males to screen for certain cancer-related markers. The tests included in this package focus on assessing markers that are commonly associated with cancer, particularly prostate cancer and pancreatic cancer. Here’s a breakdown of the tests included in this package:

Significance of the Package: The “Cancer Advance Package- Male” is designed to provide an assessment of cancer-related markers that are relevant to males, particularly for prostate cancer and pancreatic cancer. Prostate cancer is one of the most common cancers among males, and PSA (Prostate Specific Antigen) is a marker commonly used for screening and monitoring this type of cancer. Similarly, CA 19.9 is a marker that can indicate pancreatic cancer.

It’s important to note that abnormal levels of these markers do not necessarily indicate cancer. Further evaluation and discussions with a healthcare provider are needed to determine the significance of any abnormal results. Cancer screening and early detection can be valuable tools in managing health, and packages like this one offer a convenient way to assess specific cancer-related markers.

As always, the interpretation of test results and appropriate follow-up actions should be discussed with a qualified healthcare provider. Consulting with a doctor who can provide personalized guidance based on your medical history and risk factors is recommended.